

May 8, 2025

The Honorable John Cornyn  
517 Hart Senate Office Building  
Washington, DC 20510

The Honorable Richard Blumenthal  
503 Hart Senate Office Building  
Washington, DC 20510

The Honorable Chuck Grassley  
135 Hart Senate Office Building  
Washington, DC 20510

The Honorable Richard Durbin  
711 Hart Senate Office Building  
Washington, DC 20510

Dear Senators Cornyn, Grassley, Blumenthal and Durbin,

On behalf of Vizient, Inc., I am pleased to again offer our endorsement for the *Drug Competition Enhancement Act* (S.1040). Your important, bipartisan legislation would prohibit product hopping by drug manufacturers and authorize the Federal Trade Commission (FTC) to enforce this prohibition, with the goal of preventing abuse of the abbreviated new drug and biosimilar biological product application systems.

Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents \$140 billion in annual purchasing volume enabling the delivery of cost effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

Marketplace competition is critical to reducing drug costs for providers and patients. S. 1040 would promote competition by addressing the practice of product hopping, where brand-name drug manufacturers make slight modifications to existing drugs to extend patent protections and delay generic competition. By prohibiting the practice of product hopping and enabling the FTC to enforce this prohibition, this legislation will deter manipulative tactics that hinder the availability of more affordable generic medications.

We appreciate that this legislation strikes an appropriate balance between fostering innovation and promoting competition, and we are proud to offer our support. Thank you for your leadership in introducing these bills. Please do not hesitate to contact me at [shoshana.krillow@vizientinc.com](mailto:shoshana.krillow@vizientinc.com) or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krillow  
Senior Vice President, Public Policy & Government Relations

May 8, 2025

The Honorable John Cornyn  
517 Hart Senate Office Building  
Washington, DC 20510

The Honorable Richard Blumenthal  
503 Hart Senate Office Building  
Washington, DC 20510

The Honorable Chuck Grassley  
135 Hart Senate Office Building  
Washington, DC 20510

The Honorable Richard Durbin  
711 Hart Senate Office Building  
Washington, DC 20510

Dear Senators Cornyn, Grassley, Blumenthal and Durbin,

On behalf of Vizient, Inc., I am pleased to again offer our endorsement for the *Affordable Prescriptions for Patients Act* (S.1041). Your important, bipartisan legislation would encourage market competition by addressing the infringement of patents that claim biological products, or patent thickets, ultimately making it easier for generic and biosimilar drugs to enter the market, ultimately lowering the price of prescription drugs.

Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents \$140 billion in annual purchasing volume enabling the delivery of cost effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

Patent thickets, or multiple patents filed on a single existing product to extend the product's patent life, impede competition and the high cost of challenging multiple patents in court serves as a major deterrent for generic and biosimilar drugs to enter the market. By limiting the number of patents that can be asserted in litigation to 20, with no more than 10 issued after a certain date, this legislation seeks to streamline the patent dispute resolution process and ultimately facilitate quicker access to more cost-effective biosimilar drugs.

We appreciate that this legislation strikes an appropriate balance between fostering innovation and promoting competition, and we are proud to offer our support. Thank you for your leadership in introducing these bills. Please do not hesitate to contact me at [shoshana.krillow@vizientinc.com](mailto:shoshana.krillow@vizientinc.com) or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krillow  
Senior Vice President, Public Policy & Government Relations